Table 1B.
Case report and cases series with JAK inhibitors in vitiligo.
| Authors | Nation | Treatment | Drug type | Patient | Presentation at baseline | Results | Side effect | |
|---|---|---|---|---|---|---|---|---|
| Ruxolitinib | Harris et al. (19) | The United States | Ruxolitinib 20 mg orally twice daily | JAK1/2 inhibitor | 1 | Macular depigmentation on his face, trunk, and extremities | 51% facial pigmentation compared to 0.8% at baseline | No side effects |
| Tofacitinib | Craiglow et al. (33) | The United States | Tofacitinib 5 mg every other day for a week, then 5 mg daily | JAK 1/3 inhibitor | 1 | White macules and patches involving the forehead, trunk, and extremities involving approximately 10% of body surface area | Approximately 5% of the total body surface area remained depigmented | No side effects |
| Liu et al. (34) | The United States | Tofacitinib 5–10 mg daily or twice daily | JAK 1/3 inhibitor | 10 | 8 generalized vitiligo, 2 acral involvement | 5 patients who achieved some reversal of disease, re-pigmentation occurred only in sun-exposed areas of skin in 3 of them | No side effects | |
| Kim et al. (35) | The United States | Tofacitinib 5 mg twice daily, plus low-dose, narrow-band UV-B twice weekly | JAK 1/3 inhibitor | 2 | Patient 1: white patches involving about 75% of her face as well as white patches on the neck, chest, forearms, hands, and shins Patient 2: 90% of his face, as well as white patches on the torso and arms |
Patient 1: nearly complete re-pigmentation of her face 75% or greater re-pigmentation of her neck, chest, forearms, shins, and only minimal freckling of the dorsal hand Patient 2: 75% facial re-pigmentation. No re-pigmentation occurred at the other body sites |
No side effects | |
| Tofacitinib | Mobasher et al. (36) | The United States | Topical use of 2% tofacitinib twice daily | JAK 1/3 inhibitor | 16 | – | 13 >90% repigmentation; 5 25–75% repigmentation; 4 5–15(%) repigmentation; 2 no change |
No side effects |
| Baricitinib | Mumford et al. (37) | Australia | Oral baricitinib 4 mg daily | JAK1/2 inhibitor | 1 | Vitiligo affecting the hands and forearms | Amost complete re-pigmentation of the hands and forearms was observed | No side effects |